FDA Approves Artivion's AMDS Hybrid Prosthesis for Acute Aortic Dissections, Targeting $150M Market
AORT sits 24% above its 52-week low of $19.16 on elevated volume (3.5× avg).
Summary
Artivion has received U.S. FDA approval for its AMDS Hybrid Prosthesis, a significant regulatory milestone for the world's first aortic arch remodeling device for acute DeBakey Type I aortic dissections. This approval removes the prior institutional review board (IRB) requirement, which is expected to accelerate adoption and allow the company to fully penetrate an estimated $150 million annual U.S. market opportunity. Clinical data from the PERSEVERE trial showed a 72% reduction in all-cause mortality and a 54% reduction in major adverse events. This follows the company's recent FDA approval for its Nexus Aortic Arch System in April and a $135 million acquisition of Endospan in May, further strengthening its aortic solutions portfolio.
At the time of this announcement, AORT was trading at $23.78 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $19.16 to $48.25. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: PR Newswire.